Cardiology drug adherence data: Real-time stats on Medisafe that pharma should know

|

article image
The WHO estimates the average medication adherence rate is 50% in developed nations. Compared to the top 15 most adherent countries on Medisafe, the U.S. healthcare system ranks among the lowest. How do cardiology drug adherence rates vary by day and time? Type of heart treatment? Number of meds taken simultaneously? Which pharma companies manufacture drugs with the highest adherence rates on Medisafe? Download this infographic for comparative data and valuable insider insights on cardiology drug adherence that pharma companies should consider for their products and marketing strategies.

Spotlight

GNA Medical Genetics Center Ltd.

GNA Medical center is a new, state-of-the-art service provider designated solely to the practice of Genetic Medicine diagnostics. GNA center provides comprehensive, individually customized genetic analysis, employing highly advanced methods and technology known in the field of genetic diagnosis, and a unique concept, the first of its kind in Israel.

OTHER ARTICLES

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 1, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | April 1, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | April 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Spotlight

GNA Medical Genetics Center Ltd.

GNA Medical center is a new, state-of-the-art service provider designated solely to the practice of Genetic Medicine diagnostics. GNA center provides comprehensive, individually customized genetic analysis, employing highly advanced methods and technology known in the field of genetic diagnosis, and a unique concept, the first of its kind in Israel.

Events